OKYO Pharma Limited U.S. Patent issued for use of OK-101 to treat DED (4841V)
December 14 2021 - 1:59AM
UK Regulatory
TIDMOKYO
RNS Number : 4841V
OKYO Pharma Limited
14 December 2021
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES
OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK
LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS
(SI 2019/310) ("UK MAR"). UPON THE PUBLICATION OF THIS
ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW
CONSIDERED TO BE IN THE PUBLIC DOMAIN.
OKYO Pharma Limited
("OKYO" or the "Company")
OKYO Pharma announces issuance of U.S. Patent No. 11,197,906
covering OKYO Pharma's drug candidate OK-101 for use to treat dry
eye disease
London and Boston, MA, December 14, 2021 - OKYO Pharma Limited
(LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the
discovery and development of novel molecules to treat inflammatory
dry eye diseases and ocular pain, today announced that the patent
entitled "Methods of Lowering Blink Reflex for the Treatment of Dry
Eye Disease" has been issued by the United States Patent and
Trademark Office ("USPTO") as U.S. Patent No. 11,197,906. This
patent contains key claims covering OK-101 to treat dry eye
disease. OK-101 is OKYO's lead pre-clinical compound and is a novel
long-acting GPCR-based anti-inflammatory drug candidate. The work
recited in this patent lays out the potential of OK-101, a
lipidated chemerin analogue, to treat patients with dry eye disease
("DED"). The drug, planned to be administered topically, is
anticipated to open human studies with a Phase 2 clinical trial in
DED patients in Q4, 2022.
"We have made significant progress with our pre-IND work on
OK-101 and are planning to file the IND to treat DED in Q3 2022,
followed by the commencement of a Phase 2 trial in DED patients in
Q4 2022," said Dr. Gary S. Jacob, CEO of OKYO. "We believe that
OK-101 can provide a new way to treat DED patients who are
presently not well served by drugs presently approved for treating
dry eye disease."
The person who arranged for the release of this announcement on
behalf of the Company was Gary S. Jacob, Ph.D., Chief Executive
Officer of OKYO.
Enquiries:
Gary S. Jacob, Chief Executive
Officer
Gabriele Cerrone, Non-Executive +44 (0)20 7495
OKYO Pharma Limited Chairman 2379
Optiva Securities
Limited +44 (0)20 3981
(Broker) Robert Emmet 4173
RedChip Companies Dave Gentry dave@redchip.com
Inc.
(Investor Relations) +1 407-491-4498
Notes for Editors:
About OKYO
OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF) is a life sciences
and biotechnology company admitted to listing on the standard
segment of the Official List of the UK Financial Conduct Authority
and to trading on the main market for listed securities of London
Stock Exchange plc. OKYO is focusing on the discovery and
development of novel molecules to treat inflammatory dry eye
diseases and chronic pain.
About OK-101
OK-101 is a lipidated chemerin peptide antagonist of the ChemR23
G-protein coupled receptor which is typically found on
immunological cells of the eye responsible for the inflammatory
response. OK-101 was developed using a membrane-anchored-peptide
(MAP) Technology to produce a novel long-acting drug candidate for
treating DED. OK-101 has been shown to produce anti-inflammatory
activity in mouse models of DED and is designed to combat washout
through the inclusion of the lipid 'anchor' contained in the
candidate drug molecule to enhance the residence time of OK-101
within the ocular environment.
About Dry Eye Disease (DED)
Dry eye is a multifactorial disease that results in ocular
discomfort and tear film instability that can lead to ocular
surface damage. It is often a chronic problem, particularly in
older adults, and is expected to become even more prevalent with
the aging population and increased use of digital screens such as
computers and smart phones. Despite new product approvals, dry eye
disease (DED) remains a significant unmet medical need and is one
of the leading causes for patient visits to eye care specialists.
Novel therapies that improve the signs and symptoms of dry eye
disease will be beneficial to dry eye patients.
Certain statements made in this announcement are forward-looking
statements. These forward-looking statements are not historical
facts but rather are based on the Company's current expectations,
estimates, and projections about its industry; its beliefs; and
assumptions. Words such as 'anticipates,' 'expects,' 'intends,'
'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions
are intended to identify forward-looking statements. These
statements are not guarantees of future performance and are subject
to known and unknown risks, uncertainties, and other factors, some
of which are beyond the Company's control, are difficult to
predict, and could cause actual results to differ materially from
those expressed or forecasted in the forward-looking statements.
The Company cautions security holders and prospective security
holders not to place undue reliance on these forward-looking
statements, which reflect the view of the Company only as of the
date of this announcement. The forward-looking statements made in
this announcement relate only to events as of the date on which the
statements are made. The Company will not undertake any obligation
to release publicly any revisions or updates to these
forward-looking statements to reflect events, circumstances, or
unanticipated events occurring after the date of this announcement
except as required by law or by any appropriate regulatory
authority.
For further information, please visit the Company's website at
www.okyopharma.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCGPGUAPUPGGAW
(END) Dow Jones Newswires
December 14, 2021 01:59 ET (06:59 GMT)
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Sep 2024 to Oct 2024
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Oct 2023 to Oct 2024